Header Logo

Connection

DAVID NIELSEN to Cocaine-Related Disorders

Back to Details
This is a "connection" page, showing publications DAVID NIELSEN has written about Cocaine-Related Disorders.
DAVID NIELSEN
Connection Strength
7.675
Cocaine-Related Disorders
  1. Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. Eur J Clin Pharmacol. 2022 Jun; 78(6):965-973.
    View in: PubMed
    Score: 0.672
  2. The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients. Psychiatr Genet. 2021 06 01; 31(3):88-94.
    View in: PubMed
    Score: 0.638
  3. Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant. Am J Drug Alcohol Abuse. 2020; 46(2):184-193.
    View in: PubMed
    Score: 0.579
  4. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. Am J Addict. 2019 07; 28(4):311-317.
    View in: PubMed
    Score: 0.553
  5. Genetic moderation of cocaine subjective effects by variation in the TPH1, TPH2, and SLC6A4 serotonin genes. Psychiatr Genet. 2017 10; 27(5):178-186.
    View in: PubMed
    Score: 0.495
  6. Serotonin transporter gene promoter polymorphism predicts relationship between years of cocaine use and impulsivity. Psychiatr Genet. 2015 Oct; 25(5):213-4.
    View in: PubMed
    Score: 0.431
  7. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. Am J Addict. 2015 Jan; 24(1):15-23.
    View in: PubMed
    Score: 0.409
  8. A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study. Genes Brain Behav. 2014 Jul; 13(6):559-64.
    View in: PubMed
    Score: 0.387
  9. The ?-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr Genet. 2013 Dec; 23(6):225-32.
    View in: PubMed
    Score: 0.379
  10. ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics. 2013 Jul; 23(7):333-40.
    View in: PubMed
    Score: 0.369
  11. DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett. 2013 Apr 29; 541:29-33.
    View in: PubMed
    Score: 0.360
  12. Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a?preliminary study. Genes Brain Behav. 2012 Nov; 11(8):1001-8.
    View in: PubMed
    Score: 0.350
  13. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine ?-hydroxylase. Biol Psychiatry. 2013 Feb 01; 73(3):219-24.
    View in: PubMed
    Score: 0.347
  14. Former heroin addicts with or without a history of cocaine dependence are more impulsive than controls. Drug Alcohol Depend. 2012 Jul 01; 124(1-2):113-20.
    View in: PubMed
    Score: 0.333
  15. Promoter region variant C-824T in the TH gene modulates the subjective effects of cocaine. Am J Addict. 2023 09; 32(5):506-509.
    View in: PubMed
    Score: 0.184
  16. FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration. Am J Addict. 2018 10; 27(7):567-573.
    View in: PubMed
    Score: 0.132
  17. Pharmacogenetics of Dopamine ?-Hydroxylase in cocaine dependence therapy with doxazosin. Addict Biol. 2019 05; 24(3):531-538.
    View in: PubMed
    Score: 0.127
  18. The a-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Pharmacogenet Genomics. 2016 09; 26(9):428-35.
    View in: PubMed
    Score: 0.115
  19. Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. Neuroimage. 2016 Jan 15; 125:813-824.
    View in: PubMed
    Score: 0.108
  20. Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenet Genomics. 2015 Jun; 25(6):296-304.
    View in: PubMed
    Score: 0.105
  21. The influence of dopamine ?-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study. Pharmacogenet Genomics. 2014 Jul; 24(7):370-3.
    View in: PubMed
    Score: 0.099
  22. Variation within the serotonin (5-HT) 5-HT2C receptor system aligns with vulnerability to cocaine cue reactivity. Transl Psychiatry. 2014 Mar 11; 4:e369.
    View in: PubMed
    Score: 0.097
  23. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and a1A-adrenoceptor gene variation. Eur Neuropsychopharmacol. 2013 Nov; 23(11):1401-7.
    View in: PubMed
    Score: 0.092
  24. The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. PLoS One. 2012; 7(11):e47702.
    View in: PubMed
    Score: 0.088
  25. Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict Biol. 2011 Apr; 16(2):334-46.
    View in: PubMed
    Score: 0.076
  26. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci. 2010 Feb; 1187:184-207.
    View in: PubMed
    Score: 0.073
  27. A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology. 2009 Apr; 34(5):1185-97.
    View in: PubMed
    Score: 0.066
  28. Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromolecular Med. 2004; 5(1):85-108.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.